BRAF Fusion in Clinically Advanced Non-small Cell Lung Cancer: An Emerging Target for anti-BRAF Ther
作者头像
Moonshadow 2017-06-23
转载 273 0

From 2017 ASCO POSTER

上一篇：Differential Crizotinib Efficacy among ROS1 Fusion Partners in ROS1-Positive Non-Small-Cell Lung Can
下一篇：Clinicopathologic feature of non-small cell lung cancer (NSCLC) harboring an NTRK gene fusion
相关推荐
暂无
暂无相关推荐
评论 (0)
loading...
    回到顶部